Get the Daily Brief
Latest Biotech News
Roche and Ionis halt Huntington’s antisense programs
Roche has discontinued two Huntington’s disease studies for investigational antisense therapies developed with Ionis Pharmaceuticals, citing disappointing efficacy results and additional data from...
AstraZeneca licensing deal targets COPD drug differentiation
AstraZeneca has acquired rights to a Sino Biopharmaceutical molecule aimed at chronic obstructive pulmonary disease, in a move designed to extend its respiratory pipeline with a dual-mechanism...
Alzheimer’s: amyloid clearance case report links to downstream pathology
A JAMA case report has reported that regions showing extensive amyloid removal after amyloid-targeting therapies in Alzheimer’s disease also show reductions in subsequent neuropathologic changes....
Parkinson’s: plasma pTau biomarkers forecast dementia onset
Researchers have identified plasma phosphorylated tau biomarkers—pTau217 and pTau231—that can forecast dementia progression in Parkinson’s disease. The prospective longitudinal study reported that...
Pulmonary embolism in cancer: YEARS reduces reliance on invasive imaging
A JAMA study reports that the YEARS diagnostic algorithm performs comparably to standard computed tomographic pulmonary angiography (CTPA) for diagnosing pulmonary embolism in cancer patients,...
AI in R&D operations: McKinsey urges closed-loop redesign
A new McKinsey report argues biopharma firms need a “structural redesign” of R&D to capture AI’s full value, warning that deploying AI inside traditional stage-gate processes may only improve...
Cancer biology: CAF programs pinpoint TNBC stromal targets
Single-cell multi-omics work has mapped cancer-associated fibroblast (CAF) programs in triple-negative breast cancer (TNBC), identifying a myofibro-inflammatory signaling program that may drive...
Organ-on-chip: NIH funds new center at Texas A&M
Texas A&M University has won a $15.3 million NIH-funded center to advance organ-on-a-chip (OoC) technology, aiming to modernize chemical safety testing and potentially reduce reliance on animal...
Synthetic biology: SpudCell raises new questions about building cells
Researchers announced SpudCell, described as the first synthetic cell built from purified, nonliving components, according to a Nature-focused explainer. The work highlights a bottom-up approach:...
Neurodegeneration: long COVID brains show dopamine transporter damage
A brain imaging study from the Centre for Addiction and Mental Health (CAMH) reports dopamine system damage in long COVID patients. Published in eBioMedicine, the research used positron emission...
Regulatory setbacks in neurodegeneration and manufacturing
Roche discontinued two Huntington’s disease antisense programs with Ionis—halting the Phase 2 GENERATION HD2 study of tominersen after it failed a key efficacy objective and stopping a separate...
FDA changes to complete response letter cadence
The FDA resumed issuing complete response letters (CRLs), posting 14 new rejection letters after a pause linked to calls for greater transparency. The move comes after HHS confirmed to Endpoints...
AI operating model debate for biopharma R&D
McKinsey argued that biopharma companies need “structural redesign” to get full value from AI in drug development, warning that incremental workflow efficiency won’t create “compound learning.”...
Clinical validation for colorectal cancer screening blood test
Freenome’s updated SimpleScreen CRC blood test met primary and secondary endpoints in a clinical validation study, with stakeholders reacting as mixed due to trade-offs in sensitivity details. The...
Biomarker advances in Parkinson’s disease progression
Researchers identified plasma phosphorylated tau biomarkers—pTau217 and pTau231—that forecast dementia progression in patients with Parkinson’s disease. The prospective longitudinal work aims to...
Home-based diagnostics for cerebrovascular disease and sleep
Two home-technology studies in neuro care advanced non-invasive monitoring approaches. KAIST researchers unveiled an AI system to detect early cerebrovascular disease signs at home using...
Cancer biology—immune escape and angiogenesis targets
New solid-tumor research highlighted mechanisms that can blunt treatment effectiveness and sustain growth. In British Journal of Cancer, investigators reported that TP53 mutations push CD8+ T...
Organs-on-chip funding push to reduce animal testing
Texas A&M University researchers received NIH funding to expand organ-on-a-chip technology aimed at chemical safety testing. Led by Dr. Arum Han, the effort is part of a $15.3 million NIH-funded...
Carbon and infection intelligence—real-time pathogen tracking via wastewater
Scientists reported a method for real-time estimation of pathogen transmission dynamics using wastewater analysis, aiming to support outbreak surveillance without relying solely on clinical case...
Funding and IPO pipeline—Apnimed advances IPO while FDA reviews
Apnimed moved ahead with an IPO filing while the FDA reviews its sleep apnea drug, marking a step toward a potential public-market catalyst for the Cambridge, Massachusetts-based biotech. The...